Direct compression of apixaban for oral tablets is handled as a low-dose blend problem rather than a simple mixing step. At dose strengths of 2.5 mg and 5 mg in a 150–300 mg core, the drug substance can account for 0.8–3.3 wt%, so segregation potential between micronized active pharmaceutical ingredient and coarse excipients controls final uniformity. A standard pre-blend sequence passes the active through a 500 µm or 600 µm mesh together with equal parts of lactose monohydrate and microcrystalline cellulose, then combines with the remaining diluent, croscarmellose sodium 2–4 wt%, povidone K30 2–4 wt% as dry binder, and colloidal silicon dioxide 0.2–0.5 wt%. Magnesium stearate is added last at 0.5–1.0 wt%, with total lubrication not exceeding 5 min at 15–25 rpm in a bin blender. The blend is discharged through a split-valve intermediate bulk container to a rotary tablet press fitted with 6 mm round flat-faced bevel-edged tooling. Content uniformity testing according to USP <905> acceptance value ≤15 is required for the first three compression campaigns and after any change in active pharmaceutical ingredient lot particle size distribution. During high-speed compression above 80,000 tablets per hour, excessive force-feeder speed can induce particle size sorting and cause individual tablet assay drift outside 90.0–110.0% of label claim; the limit should be verified by stratified tablet sampling under USP <905> procedures. If relative humidity in dispensing and compression exceeds 60%, the active pharmaceutical ingredient and excipients are equilibrated for 4 h at 25°C before weighing and the blended powder is compressed within 4 h. Hardness is maintained in a narrow range because apixaban dissolution from direct compression matrices is sensitive to compression force; a tablet hardness above 8 kp can extend disintegration beyond the USP <701> limit and suppress early dissolution in 0.1 M hydrochloric acid media. For tablet cores without film coating, friability must remain below 1.0% according to USP <1216>; aqueous film-coating dispersion based on polyvinyl alcohol or hypromellose is applied to 2–4% weight gain for light protection and swallowability. Micronized apixaban with a D90 below 30 µm is selected when dissolution rate is limiting; unmicronized material is not recommended for direct compression unless a solubility-enhancing formulation is demonstrated.

When high-shear wet granulation is the chosen route for low-dose apixaban tablets

When high-shear wet granulation is selected, the process objective shifts from avoiding segregation to controlling granule porosity and active pharmaceutical ingredient dissolution rate. Apixaban has low aqueous solubility, so dry blending is not always sufficient to meet USP <711> dissolution criteria in quality control media. In a 600 L high-shear mixer, apixaban is dry-mixed with lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium for 6–10 min at impeller 150–250 rpm and chopper 1000–1500 rpm. A binder solution containing povidone K30 or hypromellose 3–5 wt% and sodium lauryl sulfate 0.5–1.0 wt% in purified water is added at a controlled spray rate of 0.5–1.0 kg/min per 100 kg batch. The binder solution is prepared at 40–50°C and cooled to 25°C before spraying; the liquid pH is maintained between 4.0 and 6.0 because apixaban stability is pH-sensitive and strongly alkaline granulation media are not recommended. The granulation endpoint is monitored by impeller power consumption and torque rise; the target torque plateau corresponds to a granule moisture content of 15–25 wt% depending on binder level. Wet mass is passed through a cone mill fitted with a 6–10 mm screen and dried in a fluid-bed dryer with inlet air at 50–60°C until loss on drying is 1.5–2.5 wt%. The dry granules are sized through a 1.0 mm screen and blended with extragranular croscarmellose sodium 2 wt%, magnesium stearate 0.7 wt%, and optionally talc 1.0 wt%. The final blend is compressed to tablets with a hardness of 4–7 kp. Over-wetting during binder addition produces dense, hard granules that retain high residual moisture after drying and reduce dissolution in pH 6.8 phosphate buffer; under-wetting produces weak granules that break into fines during drying and transfer, recreating segregation and poor content uniformity. Because wet granulation introduces water and heat, polymorphic stability of apixaban must be confirmed by X-ray diffraction after drying; if the diffraction pattern shows conversion to a solvate or hydrate, the solvent system and drying temperature must be revised before release. The granulation process is considered robust only when dissolution in 0.1 M hydrochloric acid meets the immediate-release Q value for both 2.5 mg and 5 mg strengths, tested according to USP <711> paddle apparatus at 75 rpm. Residual solvent is controlled to ICH Q3C limits if non-aqueous binder systems are used.

Roller compaction is adopted when the active pharmaceutical ingredient and excipients are moisture-sensitive or when wet granulation produces unacceptable polymorphic change. Apixaban is pre-blended with lactose monohydrate and microcrystalline cellulose, with 1–3 wt% crospovidone intragranular disintegrant and copovidone 5–8 wt% as dry binder. The blend is compacted on a roller compactor with a roll pressure of 20–40 kN and a roll speed of 3–8 rpm; ribbon density is maintained between 0.85 and 1.15 g/cm³. Ribbons with density below 0.8 g/cm³ tend to crumble into excessive fines during milling, while ribbons above 1.2 g/cm³ lose compressibility and produce tablets with extended disintegration. The ribbons are milled through a 1.0–1.25 mm screen, and granules are sieved to remove particles larger than 1.25 mm. The granulate is lubricated with 0.5–1.0 wt% magnesium stearate and compressed under the same tablet parameters as direct compression. USP <905> content uniformity testing is essential after compaction because the dry granulation step can generate fine active-rich particles that segregate in the hopper if the milled granule size distribution is not balanced. Hardness and disintegration are monitored with USP <701>; tablet hardness above 8 kp is not recommended unless dissolution data at pH 6.8 phosphate buffer confirm no delay in active release.

What Limits Powder Transfer from IBC to High-Speed Capsule Fillers at 2.5 mg Potency?

Encapsulation of apixaban into size 3 or size 4 hard gelatin or hypromellose capsules introduces constraints distinct from tablet compression. In low-dose capsule filling, the powder blend must possess sufficient flow to fill a 2.5 mg dose into size 3 capsules with coefficient of variation for fill weight below 2.0%. Tamping-pin style capsule fillers with powder bed height control are preferred over dosator nozzles when the active pharmaceutical ingredient is micronized and poorly flowable. A typical capsule blend contains apixaban, lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium 1–3 wt%, colloidal silicon dioxide 0.2–0.5 wt%, and sodium stearyl fumarate 1.0–1.5 wt% as lubricant. Blend uniformity is tested before and after fill, with acceptance according to USP <905> using 10 dosage units. During high-speed encapsulation above 50,000 capsules per hour, powder bed compaction in the hopper can reduce fill weight by 3–5% over a 90-minute run; therefore fill weight, capsule weight, and disintegration are sampled at the start, middle, and end of the batch. Capsule shell compatibility with the blend is confirmed by storage at 25°C/60% RH and 40°C/75% RH in high-density polyethylene bottles, with assay and dissolution tested at 0, 1, 2, and 3 months. Gelatin cross-linking is mitigated by maintaining capsule shell moisture at 13–16% and avoiding aldehyde-containing impurities. Dissolution of apixaban capsules is performed in USP <711> apparatus 2 at 75 rpm with 900 mL 0.1 M hydrochloric acid or pH 6.8 phosphate buffer; if the capsule shell delays release, hypromellose capsules are tested against the specified Q value.

Oral Granules and Suspension Vehicles for Dose-Divisible Sachet Filling

When apixaban is formulated as oral granules or powder for suspension, the production route is designed for dose flexibility in patients who cannot swallow solid oral dosage forms. The granulate is prepared by dry blending micronized apixaban with sorbitol, xylitol, or mannitol as bulking agents, dispersible cellulose, and a suspending agent such as xanthan gum 0.2–0.6 wt% or microcrystalline cellulose/sodium carboxymethylcellulose blends. The blend is wet-granulated with a solution of povidone K30 2–4 wt% in purified water, dried at not more than 50°C to avoid degradation, and sieved through a 0.8 mm screen. The final granules are filled into single-dose sachets or multi-dose containers with a desiccant. The active pharmaceutical ingredient particle size in suspension determines sedimentation and dose accuracy; if the D90 is not below 20 µm, larger crystals settle within 5 min and compromise delivery uniformity. Reconstitution is performed by adding 10–20 mL of purified water to the sachet, shaking for 30 s, and administering immediately. pH of the dispersion is maintained between 4.0 and 6.0 to reduce chemical degradation of apixaban in aqueous media. The viscosity of the vehicle is adjusted with xanthan gum to 200–600 mPa·s at 25°C to balance pourability and sedimentation rate. Chemical stability of apixaban in this presentation is evaluated according to ICH Q1A(R2) conditions; assays by high-performance liquid chromatography are performed at 40°C/75% RH for 3 months and 25°C/60% RH for 12 months. Dissolution testing for granules is carried out with USP <711> apparatus 2 under sink conditions, and multi-dose containers must deliver the labeled quantity according to USP <698> if applicable. This presentation is not a correction for poor blending; it is a distinct formulation with its own content uniformity limits and degradation profile, and it cannot be substituted with crushed apixaban tablets without bioequivalence data.

Injectable Formulation Boundaries Set by Thermodynamic Solubility, Particulate Loading, and Terminal Sterilization

Injectable formulation of apixaban requires control of aqueous solubility, particle size, sterility, and pyrogen load. Apixaban is practically insoluble in water, so a simple aqueous solution cannot be achieved without a solubility-enhancing strategy such as 10–30% v/v polyethylene glycol 300, 10–20% v/v propylene glycol, or cyclodextrin inclusion complexes. The active pharmaceutical ingredient content per container depends on whether the intended product is a solution, suspension, or nanosuspension. For a nanosuspension suitable for intravenous delivery, the particle size is reduced by wet-ball milling or high-pressure homogenization with stabilizers such as polysorbate 80 0.5–1.0 wt% and sodium lauryl sulfate 0.1–0.3 wt%; the final mean particle size must be below 500 nm to avoid capillary obstruction. Sterile filtration through a 0.22 µm membrane is feasible only for true solutions or particle-free solutions; for suspensions, terminal sterilization by autoclaving at 121°C for 15 min is evaluated for chemical stability because apixaban may undergo degradation in aqueous media at high temperature. If terminal sterilization is not acceptable due to assay reduction or impurity increase, aseptic processing under ISO 5 or EU GMP Annex 1 conditions is required. Particulate matter in the finished injection must comply with USP <788> for large-volume parenterals or USP <789> for small-volume injections; subvisible particles ≥10 µm and ≥25 µm are counted by light obscuration, and the limits are not more than 6000 per container and not more than 600 per container for small-volume injections, depending on container volume. Sterility testing is performed according to USP <71> by membrane filtration with soybean-casein digest medium and fluid thioglycollate medium; endotoxin content is limited according to USP <85> based on maximum dose. Residual solvents from co-solvent systems must satisfy ICH Q3C, and elemental impurities are controlled to USP <232>/<233> and ICH Q3D. Published data for this specific injectable configuration are limited; the stated boundaries are derived from compendial parenteral requirements rather than an approved apixaban injection product. The injectable route is not a simple extension of oral formulation; the active pharmaceutical ingredient must be accompanied by a drug master file that includes particle size distribution, microbial limit, bacterial endotoxin limit, and container closure compatibility data because final product sterility cannot be assured by chemical testing alone.